FDA approved olaparib capsules (Lynparza, AstraZeneca Pharmaceuticals LP) as monotherapy for the treatment of patients with deleterious or suspected deleterious germline BRCA mutated (gBRCAm) (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. December 19, 2014. More Information: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm427598.htm